Actively Recruiting
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Led by Humanity & Health Medical Group Limited · Updated on 2025-03-24
2000
Participants Needed
1
Research Sites
369 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.
CONDITIONS
Official Title
Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HBsAg positive, HBeAg negative, and antibody to HBeAg positive
- Stable use of anti-HBV nucleos(t)ide analogue mono therapy for more than one and a half years
- Undetectable HBV DNA on three occasions, each at least 6 months apart, consistent with APASL stopping rule
- Ability to read, understand, and sign the study consent form
You will not qualify if you...
- Presence of other liver diseases
- Concurrent infection with other hepatitis viruses or HIV
- Reluctance to stop anti-HBV treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Humanity & Health Research Centre
Hong Kong, Hong Kong SAR, Hong Kong
Actively Recruiting
Research Team
G
George Lau, MD
CONTACT
D
Danny Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here